We are an emerging leader with new solutions in the field of nuclear medicine technology

Our innovative products and technologies are designed to meet current and future demands for medical radioisotopes. They mark a new era for nuclear medicine technology.

Discover our Products

Supply

Medical radioisotopes are critical to meet patient healthcare needs and advance clinical research. We’ve charted the course for producing a stable, reliable and domestically sourced isotope supply.

Explore our Processes

Commitment

Our people drive our solutions. From providing domestic supply of isotopes for patients to national security and environmental sustainability, we are committed to advancing radioisotope technology to shape a better world.

Learn More

About NorthStar

We are a nuclear medicine technology company committed to providing the United States with stable, domestic and environmentally friendly radioisotope supply solutions to meet the needs of patients and advance clinical research. Our innovative technologies have the ability to fundamentally transform the ways that medical radioisotopes are produced and distributed around the world.

Learn More About NorthStar

Inside NorthStar

July 17, 2019

NorthStar Medical Radioisotopes Announces Construction Completion of Beloit, Wisconsin Processing Facility for Expanded Domestic Production of Medically Important Molybdenum-99 (Mo-99)

─ Facility part of staged, dual production pathway plan to expand Mo-99 production and efficiency in parallel with RadioGenix® System enhancements ─ RadioGenix System customers provided with reliable Mo-99 supply throughout eight months since commercial launch, helping mitigate concurrent industry disruptions BELOIT, Wis.

Press Releases

June 12, 2019

NorthStar Medical Radioisotopes Announces Presentations on Mo-99 Supply and the RadioGenix® System at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

BELOIT, Wis. – June 12, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced upcoming presentations at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 22 – 26, 2018 in Anaheim, Ca.

Press Releases

April 23, 2019

NorthStar Medical Closes $100 Million Financing with Oberland Capital to Expand Domestic Mo-99 Radioisotope Production Capacity and Implement RadioGenix® System Enhancements

BELOIT, Wis. – April 23, 2019 – NorthStar Medical Technologies, LLC, (“NorthStar” or the “Company”) a global innovator in the production and distribution of radioisotopes used for medical imaging and therapy, today announced the closing of a $100 million secured financing with funds managed by Oberland Capital Management LLC (“Oberland Capital”).

We are an emerging leader with new solutions in the field of nuclear medicine technology

About NorthStar

How Can We Help?